Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM9JZ21)

• Drug Name: Scriptaid Drug Info
• Synonyms: CGK1026; IN1099; SB-556629; GNF-PF-2024; N-Hydroxy-1,3-dioxo-1H-benz(de)isoquinoline-2(3H)-hexan amide; 6-(1,3-Dioxo-1H,3H-benzo[de]isoquinolin-2-yl)-hexanoic acid hydroxyamide; 6-(1,3-Dioxo-1H-benzo[de]isoquinolin-2(3H)-yl)-N-hydroxyhexanamide; 6-(1,3-dioxobenzo[de]isoquinolin-2-yl)-N-hydroxyhexanamide

Indication

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Preclinical	[1]

• Cross-matching ID:
  PubChem CID: 5186
  ChEBI ID: CHEMBL92401
  CAS Number: CAS 287383-59-9
  TTD Drug ID: DM9JZ21

Molecule-Related Drug Atlas

Drug(s) Targeting Histone deacetylase 1 (HDAC1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Vorinostat	DMWMPD4	Adult acute monocytic leukemia		Approved	[4]
Romidepsin	DMT5GNL	Cutaneous T-cell lymphoma	2B01	Approved	[5]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[4]
HBI-8000	DMDWYUN	Non-small-cell lung cancer	2C25.Y	Registered	[6]
ITF2357	DMFZBNE	Duchenne dystrophy	8C70	Phase 3	[7]
NVP-LAQ824	DM8JWNA	Mood disorder	6A60-6E23	Phase 3	[8]
SNDX-275	DMH7W9X	Breast cancer	2C60-2C65	Phase 3	[9]
Phenylbutyrate	DMBHPDW	Urea cycle disorder	5C50.A	Phase 2	[10]
MGCD-0103	DM726HX	Non-small-cell lung cancer	2C25.Y	Phase 2	[4]
Resminostat	DMNE1FR	Hepatocellular carcinoma	2C12.02	Phase 2	[11]

Drug(s) Affected By Putative POTE ankyrin domain family member M (POTEM)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[12]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[13]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[13]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[14]
Vorinostat	DMWMPD4	Adult acute monocytic leukemia		Approved	[15]
SNDX-275	DMH7W9X	Breast cancer	2C60-2C65	Phase 3	[15]
Nabiximols	DMHKJ5I	Cancer related pain	MG30	Phase 3	[16]
MGCD-0103	DM726HX	Non-small-cell lung cancer	2C25.Y	Phase 2	[15]
(+)-JQ1	DM1CZSJ	Testicular cancer	2C80	Phase 1	[17]
Tacedinaline	DM1Z74X	Solid tumour/cancer	2A00-2F9Z	Discontinued in Phase 2	[15]

Drug(s) Affected By Huntingtin-interacting protein 1 (HIP1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[18]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[19]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[20]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[15]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[21]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[22]
Ethanol	DMDRQZU	Chronic pain	MG30	Approved	[23]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[24]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[25]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[26]

Drug(s) Affected By Transcription factor E2F3 (E2F3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[27]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[28]
Acetic Acid, Glacial	DM4SJ5Y	infection in the ear canal	AA0Y	Approved	[29]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[30]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[31]
Testosterone enanthate	DMB6871	N. A.	N. A.	Approved	[32]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[33]
Motexafin gadolinium	DMEJKRF	Brain cancer	2A00	Approved	[29]
Menthol	DMG2KW7	Back pain	ME84.Z	Approved	[34]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[35]

Drug(s) Affected By Cyclin-dependent kinase 2-associated protein 1 (CDK2AP1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[36]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[37]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[14]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[35]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[38]
(+)-JQ1	DM1CZSJ	Testicular cancer	2C80	Phase 1	[39]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[40]
bisphenol A	DM2ZLD7	Discovery agent	N.A.	Investigative	[41]
[3H]methyltrienolone	DMTSGOW	Discovery agent	N.A.	Investigative	[42]

Drug(s) Affected By Kinetochore protein NDC80 homolog (NDC80)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[43]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[44]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[45]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[46]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[47]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[36]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[48]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[13]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[13]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[49]

Drug(s) Affected By DNA repair protein RAD51 homolog 2 (RAD51B)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[36]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[50]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[33]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[24]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[51]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[25]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[52]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[53]
Vorinostat	DMWMPD4	Adult acute monocytic leukemia		Approved	[54]
Urethane	DM7NSI0	N. A.	N. A.	Phase 4	[55]

Drug(s) Affected By Protein MTSS 1 (MTSS1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[56]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[57]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[31]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[14]
Rosiglitazone	DMILWZR	Chronic kidney disease	GB61	Approved	[58]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[35]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[24]
Decitabine	DMQL8XJ	Acute myelogenous leukaemia	2A41	Approved	[59]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[26]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[60]

Drug(s) Affected By Transmembrane and coiled-coil domains protein 2 (TMCC2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[15]
Amiodarone	DMUTEX3	Tachyarrhythmias	BC71	Approved	[61]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[51]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[25]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[62]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[63]
Genistein	DM0JETC	Menopause symptom	GA30.0	Phase 2/3	[64]
(+)-JQ1	DM1CZSJ	Testicular cancer	2C80	Phase 1	[17]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[65]
PMID28460551-Compound-2	DM4DOUB	N. A.	N. A.	Patented	[66]

Drug(s) Affected By G2/mitotic-specific cyclin-B2 (CCNB2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[67]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[43]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[68]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[45]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[56]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[47]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[69]
Chlorpromazine	DMBGZI3	Acute intermittent hepatic porphyria	5C58.11	Approved	[70]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[71]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[13]

Drug(s) Affected By Proto-oncogene serine/threonine-protein kinase mos (MOS)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[14]
Paclitaxel	DMLB81S	Breast carcinoma		Approved	[72]
Epigallocatechin gallate	DMCGWBJ	Hepatic fibrosis	DB93.0	Phase 3	[73]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[40]
PMID28870136-Compound-52	DMFDERP	N. A.	N. A.	Patented	[73]
bisphenol A	DM2ZLD7	Discovery agent	N.A.	Investigative	[74]

Drug(s) Affected By Cystatin-C (CST3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Selenium	DM25CGV	N. A.	N. A.	Approved	[75]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[76]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[20]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[77]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[78]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[37]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[21]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[79]
Gentamicin	DMKINJO	Bacteremia	1A73	Approved	[80]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[24]

Drug(s) Affected By Sodium/potassium-transporting ATPase subunit beta-1 (ATP1B1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[36]
Isoniazid	DM5JVS3	Latent tuberculosis infection		Approved	[81]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[82]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[13]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[13]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[83]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[14]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[22]
Diethylstilbestrol	DMN3UXQ	Gonorrheal vaginitis	GA02	Approved	[84]
Piroxicam	DMTK234	Osteoarthritis	FA00-FA05	Approved	[85]

Drug(s) Affected By Plasminogen activator inhibitor 1 (SERPINE1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[86]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[87]
Spironolactone	DM2AQ5N	Chronic heart failure	BD1Z	Approved	[88]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[89]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[90]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[91]
obeticholic acid	DM3Q1SM	Primary biliary cholangitis	DB96.1	Approved	[92]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[93]
Nefazodone	DM4ZS8M	Major depressive disorder	6A70.3	Approved	[94]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[95]

Drug(s) Affected By Interferon alpha-inducible protein 6 (IFI6)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[96]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[97]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[98]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[99]
Selenium	DM25CGV	N. A.	N. A.	Approved	[75]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[100]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[56]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[101]
Methylprednisolone	DM4BDON	Acute adrenal insufficiency		Approved	[100]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[102]

Drug(s) Affected By Myb-related protein A (MYBL1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[103]
Spironolactone	DM2AQ5N	Chronic heart failure	BD1Z	Approved	[104]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[56]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[15]
Estrone	DM5T6US	Acne vulgaris	ED80	Approved	[103]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[77]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[105]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[31]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[106]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[104]

Drug(s) Affected By Ezrin (EZR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[18]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[68]
Selenium	DM25CGV	N. A.	N. A.	Approved	[75]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[107]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[108]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[109]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[110]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[111]
Haloperidol	DM96SE0	Delirium		Approved	[18]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[49]

Drug(s) Affected By Metalloproteinase inhibitor 2 (TIMP2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[68]
Nitric Oxide	DM1RBYG	Hypertension	BA00-BA04	Approved	[112]
Selenium	DM25CGV	N. A.	N. A.	Approved	[113]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[114]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[115]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[116]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[117]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[57]
Tetracaine	DM9J6C2	Spinal anesthesia	MB40.3	Approved	[118]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[119]

Drug(s) Affected By Nuclear receptor subfamily 4immunitygroup A member 1 (NR4A1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[120]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[121]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[56]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[122]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[48]
Thalidomide	DM70BU5	Adult T-cell leukemia/lymphoma		Approved	[123]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[13]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[13]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[49]
Febuxostat	DMDEXQ0	Hyperuricaemia	5C55.Y	Approved	[124]

Drug(s) Affected By CD82 antigen (CD82)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[96]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[36]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[125]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[13]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[13]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[109]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[35]
Bortezomib	DMNO38U	Leukemia		Approved	[126]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[51]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[127]

Drug(s) Affected By G-protein coupled receptor 183 (GPR183)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[128]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[15]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[82]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[15]
Pioglitazone	DMKJ485	Amyotrophic lateral sclerosis	8B60.0	Approved	[129]
Irinotecan	DMP6SC2	Adenocarcinoma	2D40	Approved	[130]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[131]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[132]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[63]
Vorinostat	DMWMPD4	Adult acute monocytic leukemia		Approved	[15]

Drug(s) Affected By Catenin beta-1 (CTNNB1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[133]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[134]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[135]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[46]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[136]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[137]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[138]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[139]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[140]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[141]

Drug(s) Affected By Centrin-2 (CETN2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[68]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[37]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[14]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[24]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[142]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[63]
Urethane	DM7NSI0	N. A.	N. A.	Phase 4	[55]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[40]
bisphenol A	DM2ZLD7	Discovery agent	N.A.	Investigative	[41]
Trichostatin A	DM9C8NX	Solid tumour/cancer	2A00-2F9Z	Investigative	[143]

Drug(s) Affected By Regulator of G-protein signaling 2 (RGS2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[68]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[128]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[144]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[56]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[108]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[145]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[125]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[78]
Acocantherin	DM7JT24	Atrial fibrillation	BC81.3	Approved	[146]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[119]

Drug(s) Affected By Cathepsin O (CTSO)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[147]
Selenium	DM25CGV	N. A.	N. A.	Approved	[75]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[31]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[14]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[148]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[31]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[63]
PDX-101	DM6OC53	Plasma cell myeloma	2A83.1	Phase 2	[54]
PEITC	DMOMN31	Prostate cancer	2C82.0	Phase 2	[149]
GSK2110183	DMZHB37	leukaemia	2A60-2B33	Phase 2	[150]

Drug(s) Affected By Collagenase 3 (MMP13)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ofloxacin	DM0VQN3	Acute gonococcal cervicitis		Approved	[151]
Clindamycin	DM15HL8	Acne vulgaris	ED80	Approved	[152]
Ciprofloxacin XR	DM2NLS9	Acute gonococcal cervicitis		Approved	[151]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[144]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[153]
Glucosamine	DM4ZLFD	Osteoarthritis	FA00-FA05	Approved	[154]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[155]
Doxycycline	DM7ICNU	Acne vulgaris	ED80	Approved	[152]
Acocantherin	DM7JT24	Atrial fibrillation	BC81.3	Approved	[146]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[156]

Drug(s) Affected By Max-interacting protein 1 (MXI1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[56]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[157]
Clodronate	DM9Y6X7	Hypercalcaemia	5B91.0	Approved	[158]
Cidofovir	DMA13GD	Cytomegalovirus infection	1D82	Approved	[158]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[31]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[33]
Ifosfamide	DMCT3I8	Adult central nervous system germ cell tumor		Approved	[158]
Demecolcine	DMCZQGK	Solid tumour/cancer	2A00-2F9Z	Approved	[159]
2-deoxyglucose	DMIAHVU	Solid tumour/cancer	2A00-2F9Z	Approved	[15]
Niclosamide	DMJAGXQ	Cestodes infection	1F70-1F76	Approved	[160]

Drug(s) Affected By Growth arrest-specific protein 1 (GAS1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[96]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[19]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[155]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[102]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[161]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[14]
Melphalan	DMOLNHF	Hematologic disease	3C0Z	Approved	[162]
Gemcitabine	DMSE3I7	Anterior urethra cancer		Approved	[163]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[164]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[165]

Drug(s) Affected By Cyclin-dependent kinase 4 inhibitor D (CDKN2D)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[134]
Etretinate	DM2CZFA	Keratosis	ED56	Approved	[166]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[167]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[101]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[168]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[13]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[13]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[37]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[169]
Menthol	DMG2KW7	Back pain	ME84.Z	Approved	[34]

Drug(s) Affected By Sestrin-3 (SESN3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[170]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[27]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[56]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[36]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[102]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[31]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[109]
Capsaicin	DMGMF6V	Back pain	ME84.Z	Approved	[171]
Mifepristone	DMGZQEF	Cushing disease	5A70	Approved	[172]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[35]

Drug(s) Affected By Cyclin-dependent kinases regulatory subunit 1 (CKS1B)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fluoxetine	DM3PD2C	Bipolar depression		Approved	[173]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[47]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[36]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[111]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[13]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[13]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[22]
Dasatinib	DMJV2EK	Blast phase chronic myelogenous leukemia, BCR-ABL1 positive		Approved	[174]
Diethylstilbestrol	DMN3UXQ	Gonorrheal vaginitis	GA02	Approved	[175]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[24]

Drug(s) Affected By Eukaryotic translation initiation factor 4 gamma 2 (EIF4G2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[12]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[176]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[176]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[176]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[177]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[22]
Menthol	DMG2KW7	Back pain	ME84.Z	Approved	[34]
Diethylstilbestrol	DMN3UXQ	Gonorrheal vaginitis	GA02	Approved	[84]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[178]
Menadione	DMSJDTY	Vitamin K deficiency	5B59	Approved	[68]

Drug(s) Affected By Pro-neuregulin-1, membrane-bound isoform (NRG1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[67]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[74]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[107]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[47]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[19]
Cyclophosphamide	DM4O2Z7	Advanced cancer	2A00-2F9Z	Approved	[179]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[109]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[110]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[31]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[14]

Drug(s) Affected By Condensin complex subunit 1 (NCAPD2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[36]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[13]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[13]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[49]
Cidofovir	DMA13GD	Cytomegalovirus infection	1D82	Approved	[158]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[31]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[14]
Ifosfamide	DMCT3I8	Adult central nervous system germ cell tumor		Approved	[158]
Palbociclib	DMD7L94	Breast cancer	2C60-2C65	Approved	[180]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[22]

Drug(s) Affected By Dual specificity protein phosphatase 6 (DUSP6)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[181]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[68]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[56]
obeticholic acid	DM3Q1SM	Primary biliary cholangitis	DB96.1	Approved	[92]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[182]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[102]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[183]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[49]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[37]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[33]

Drug(s) Affected By INO80 complex subunit D (INO80D)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Rifampicin	DM5DSFZ	Non-insulin dependent diabetes	5A11	Approved	[184]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[185]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[37]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[33]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[51]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[165]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[63]
Vorinostat	DMWMPD4	Adult acute monocytic leukemia		Approved	[15]
Urethane	DM7NSI0	N. A.	N. A.	Phase 4	[55]
SNDX-275	DMH7W9X	Breast cancer	2C60-2C65	Phase 3	[54]

Drug(s) Affected By Cyclin-J (CCNJ)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[68]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[186]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[36]
Acetic Acid, Glacial	DM4SJ5Y	infection in the ear canal	AA0Y	Approved	[29]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[186]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[49]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[37]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[33]
Motexafin gadolinium	DMEJKRF	Brain cancer	2A00	Approved	[29]
Melphalan	DMOLNHF	Hematologic disease	3C0Z	Approved	[162]

Drug(s) Affected By Male-specific lethal 1 homolog (MSL1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[15]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[33]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[25]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[63]
Vorinostat	DMWMPD4	Adult acute monocytic leukemia		Approved	[54]
(+)-JQ1	DM1CZSJ	Testicular cancer	2C80	Phase 1	[187]
PMID28460551-Compound-2	DM4DOUB	N. A.	N. A.	Patented	[66]
PMID28870136-Compound-52	DMFDERP	N. A.	N. A.	Patented	[188]
Milchsaure	DM462BT	Pruritus	EC90	Investigative	[189]
Apicidin	DM83WVF	Solid tumour/cancer	2A00-2F9Z	Investigative	[15]

Drug(s) Affected By Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase TPTE2 (TPTE2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[27]
Permethrin	DMZ0Q1G	Pediculus capitis infestation	1G00.0	Approved	[190]
Tanespimycin	DMNLQHK	Breast cancer	2C60-2C65	Phase 2	[191]
bisphenol A	DM2ZLD7	Discovery agent	N.A.	Investigative	[74]

Drug(s) Affected By Transforming growth factor beta activator LRRC33 (NRROS)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[36]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[15]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[14]
Decitabine	DMQL8XJ	Acute myelogenous leukaemia	2A41	Approved	[40]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[131]
(+)-JQ1	DM1CZSJ	Testicular cancer	2C80	Phase 1	[192]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[40]
Oxamflatin	DM1TG3C	Solid tumour/cancer	2A00-2F9Z	Terminated	[15]

Drug(s) Affected By Cohesin subunit SA-2 (STAG2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Selenium	DM25CGV	N. A.	N. A.	Approved	[75]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[193]
Clorgyline	DMCEUJD	Parkinson disease	8A00.0	Approved	[194]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[33]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[79]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[24]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[26]
Vorinostat	DMWMPD4	Adult acute monocytic leukemia		Approved	[54]
Tocopherol	DMBIJZ6	N. A.	N. A.	Phase 2	[75]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[40]

Drug(s) Affected By TBC1 domain family member 16 (TBC1D16)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[15]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[195]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[196]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[24]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[25]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[132]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[63]
Vorinostat	DMWMPD4	Adult acute monocytic leukemia		Approved	[15]
Phenobarbital	DMXZOCG	Cluster headache	8A81.0	Approved	[197]
Camptothecin	DM6CHNJ	Solid tumour/cancer	2A00-2F9Z	Phase 3	[15]

Drug(s) Affected By Nuclear receptor subfamily 4 group A member 3 (NR4A3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Mercaptopurine	DMTM2IK	Acute lymphoblastic leukaemia	2A85	Approved	[72]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[100]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[108]
Methylprednisolone	DM4BDON	Acute adrenal insufficiency		Approved	[100]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[117]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[49]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[21]
Dexamethasone	DMMWZET	Acute adrenal insufficiency		Approved	[198]
Azathioprine	DMMZSXQ	Lupus nephritis	4A40.0Y	Approved	[100]
Melphalan	DMOLNHF	Hematologic disease	3C0Z	Approved	[162]

Drug(s) Affected By Protein Jumonji (JARID2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[199]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[15]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[200]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[15]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[33]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[15]
Menadione	DMSJDTY	Vitamin K deficiency	5B59	Approved	[68]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[148]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[132]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[63]

Drug(s) Affected By ELL-associated factor 2 (EAF2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[56]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[108]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[15]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[201]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[57]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[31]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[33]
Docetaxel	DMDI269	Advanced cancer	2A00-2F9Z	Approved	[15]
Niclosamide	DMJAGXQ	Cestodes infection	1F70-1F76	Approved	[160]
Amiodarone	DMUTEX3	Tachyarrhythmias	BC71	Approved	[61]

Drug(s) Affected By Small glutamine-rich tetratricopeptide repeat-containing protein beta (SGTB)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[108]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[185]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[31]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[14]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[22]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[24]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[62]
Carbamazepine	DMZOLBI	Epilepsy	8A60-8A68	Approved	[177]
Urethane	DM7NSI0	N. A.	N. A.	Phase 4	[55]
Camptothecin	DM6CHNJ	Solid tumour/cancer	2A00-2F9Z	Phase 3	[15]

Drug(s) Affected By Small integral membrane protein 14 (SMIM14)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[15]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[13]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[13]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[31]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[33]
Docetaxel	DMDI269	Advanced cancer	2A00-2F9Z	Approved	[15]
Ampicillin	DMHWE7P	Acute epiglottitis		Approved	[56]
2-deoxyglucose	DMIAHVU	Solid tumour/cancer	2A00-2F9Z	Approved	[15]
Niclosamide	DMJAGXQ	Cestodes infection	1F70-1F76	Approved	[160]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[35]

Drug(s) Affected By Sialidase-1 (NEU1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[186]
Fluoxetine	DM3PD2C	Bipolar depression		Approved	[202]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[36]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[15]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[31]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[33]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[131]
Gemcitabine	DMSE3I7	Anterior urethra cancer		Approved	[163]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[25]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[165]

Drug(s) Affected By Metalloproteinase inhibitor 4 (TIMP4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Selenium	DM25CGV	N. A.	N. A.	Approved	[113]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[14]
Isoproterenol	DMK7MEY	Atrioventricular block		Approved	[203]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[35]
Dexamethasone	DMMWZET	Acute adrenal insufficiency		Approved	[198]
Decitabine	DMQL8XJ	Acute myelogenous leukaemia	2A41	Approved	[204]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[51]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[165]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[205]
Nicotine	DMWX5CO	Lung cancer	2C25.0	Approved	[206]

Drug(s) Affected By Cell division control protein 6 homolog (CDC6)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[67]
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[207]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[144]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[114]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[47]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[76]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[30]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[13]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[13]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[31]

Drug(s) Affected By Condensin complex subunit 3 (NCAPG)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[56]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[47]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[36]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[13]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[13]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[49]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[31]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[14]
Palbociclib	DMD7L94	Breast cancer	2C60-2C65	Approved	[180]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[22]

Drug(s) Affected By Partner of Y14 and mago (PYM1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[18]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[56]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[36]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[15]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[37]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[33]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[22]
2-deoxyglucose	DMIAHVU	Solid tumour/cancer	2A00-2F9Z	Approved	[15]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[24]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[63]

Drug(s) Affected By Protein FAM117A (FAM117A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[68]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[15]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[56]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[78]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[49]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[31]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[14]
Docetaxel	DMDI269	Advanced cancer	2A00-2F9Z	Approved	[15]
2-deoxyglucose	DMIAHVU	Solid tumour/cancer	2A00-2F9Z	Approved	[15]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[24]

Drug(s) Affected By Anaphase-promoting complex subunit 1 (ANAPC1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[208]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[36]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[209]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[22]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[24]
Gemcitabine	DMSE3I7	Anterior urethra cancer		Approved	[163]
Menadione	DMSJDTY	Vitamin K deficiency	5B59	Approved	[68]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[142]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[63]
Genistein	DM0JETC	Menopause symptom	GA30.0	Phase 2/3	[210]

Drug(s) Affected By E3 ubiquitin-protein ligase Jade-2 (JADE2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[108]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[109]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[211]
2-deoxyglucose	DMIAHVU	Solid tumour/cancer	2A00-2F9Z	Approved	[15]
Niclosamide	DMJAGXQ	Cestodes infection	1F70-1F76	Approved	[160]
Melphalan	DMOLNHF	Hematologic disease	3C0Z	Approved	[162]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[63]
Vorinostat	DMWMPD4	Adult acute monocytic leukemia		Approved	[15]
SNDX-275	DMH7W9X	Breast cancer	2C60-2C65	Phase 3	[109]
(+)-JQ1	DM1CZSJ	Testicular cancer	2C80	Phase 1	[17]

Drug(s) Affected By Anillin (ANLN)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[68]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[45]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[56]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[47]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[13]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[13]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[212]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[33]
Palbociclib	DMD7L94	Breast cancer	2C60-2C65	Approved	[180]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[22]

Drug(s) Affected By Tumor necrosis factor receptor superfamily member 19 (TNFRSF19)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[96]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[56]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[19]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[15]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[161]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[56]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[213]
Docetaxel	DMDI269	Advanced cancer	2A00-2F9Z	Approved	[15]
Azathioprine	DMMZSXQ	Lupus nephritis	4A40.0Y	Approved	[214]
Melphalan	DMOLNHF	Hematologic disease	3C0Z	Approved	[162]

Drug(s) Affected By Protein FAM217B (FAM217B)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[181]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[36]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[49]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[37]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[33]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[24]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[51]
Menadione	DMSJDTY	Vitamin K deficiency	5B59	Approved	[68]
Formaldehyde	DM7Q6M0	Discovery agent	N.A.	Investigative	[215]
crotylaldehyde	DMTWRQI	Discovery agent	N.A.	Investigative	[216]

Drug(s) Affected By Pre-mRNA-splicing factor RBM22 (RBM22)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[15]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[33]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[22]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[24]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[51]
Vorinostat	DMWMPD4	Adult acute monocytic leukemia		Approved	[169]
Urethane	DM7NSI0	N. A.	N. A.	Phase 4	[55]
TAK-243	DM4GKV2	Solid tumour/cancer	2A00-2F9Z	Phase 1	[217]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[40]
Oxamflatin	DM1TG3C	Solid tumour/cancer	2A00-2F9Z	Terminated	[15]

Drug(s) Affected By PH and SEC7 domain-containing protein 3 (PSD3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[56]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[108]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[218]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[37]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[14]
Demecolcine	DMCZQGK	Solid tumour/cancer	2A00-2F9Z	Approved	[159]
Diethylstilbestrol	DMN3UXQ	Gonorrheal vaginitis	GA02	Approved	[84]
Melphalan	DMOLNHF	Hematologic disease	3C0Z	Approved	[162]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[24]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[38]

Drug(s) Affected By Ral guanine nucleotide dissociation stimulator-like 1 (RGL1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[74]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[68]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[56]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[15]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[218]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[49]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[119]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[33]
Demecolcine	DMCZQGK	Solid tumour/cancer	2A00-2F9Z	Approved	[159]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[196]

Drug(s) Affected By Neuronal-specific septin-3 (SEPTIN3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[22]
Decitabine	DMQL8XJ	Acute myelogenous leukaemia	2A41	Approved	[204]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[51]
Vorinostat	DMWMPD4	Adult acute monocytic leukemia		Approved	[54]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[65]
PMID28460551-Compound-2	DM4DOUB	N. A.	N. A.	Patented	[66]
bisphenol A	DM2ZLD7	Discovery agent	N.A.	Investigative	[219]
acetaldehyde	DMJFKG4	Discovery agent	N.A.	Investigative	[220]
Sulforaphane	DMQY3L0	Skin disease	EA00-EM0Z	Investigative	[221]

Drug(s) Affected By Inactive cell surface hyaluronidase CEMIP2 (CEMIP2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[56]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[31]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[33]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[22]
Folic Acid	DMEMBJC	Colorectal carcinoma		Approved	[222]
2-deoxyglucose	DMIAHVU	Solid tumour/cancer	2A00-2F9Z	Approved	[15]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[35]
Bleomycin	DMNER5S	Cervical cancer	2C77.0	Approved	[15]
Hydroxyurea	DMOQVU9	Chronic myelogenous leukaemia	2A20.0	Approved	[15]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[24]

Drug(s) Affected By RING finger protein 24 (RNF24)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[56]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[36]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[15]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[82]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[31]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[54]
2-deoxyglucose	DMIAHVU	Solid tumour/cancer	2A00-2F9Z	Approved	[15]
Hydroxyurea	DMOQVU9	Chronic myelogenous leukaemia	2A20.0	Approved	[15]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[131]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[148]

Drug(s) Affected By Phosphatidylinositide phosphatase SAC2 (INPP5F)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[199]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[36]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[15]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[37]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[14]
Rosiglitazone	DMILWZR	Chronic kidney disease	GB61	Approved	[223]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[51]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[132]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[63]
Vorinostat	DMWMPD4	Adult acute monocytic leukemia		Approved	[15]

Drug(s) Affected By RWD domain-containing protein 3 (RWDD3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[15]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[31]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[33]
Niclosamide	DMJAGXQ	Cestodes infection	1F70-1F76	Approved	[160]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[24]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[142]
Vorinostat	DMWMPD4	Adult acute monocytic leukemia		Approved	[15]
Camptothecin	DM6CHNJ	Solid tumour/cancer	2A00-2F9Z	Phase 3	[15]
Pracinostat	DMTD7AB	Acute myeloid leukaemia	2A60	Phase 3	[15]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[40]

Drug(s) Affected By DmX-like protein 1 (DMXL1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[56]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[224]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[15]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[224]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[37]
Clorgyline	DMCEUJD	Parkinson disease	8A00.0	Approved	[194]
Diethylstilbestrol	DMN3UXQ	Gonorrheal vaginitis	GA02	Approved	[84]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[24]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[51]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[26]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Histone deacetylase 1 (HDAC1)	TT6R7JZ	HDAC1_HUMAN	Inhibitor	[2]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Anaphase-promoting complex subunit 1 (ANAPC1)	OT2YY35L	APC1_HUMAN	Gene/Protein Processing	[3]
Anillin (ANLN)	OTXJY54C	ANLN_HUMAN	Gene/Protein Processing	[3]
Catenin beta-1 (CTNNB1)	OTZ932A3	CTNB1_HUMAN	Gene/Protein Processing	[3]
Cathepsin O (CTSO)	OTFL6VRO	CATO_HUMAN	Gene/Protein Processing	[3]
CD82 antigen (CD82)	OTH8MC64	CD82_HUMAN	Gene/Protein Processing	[3]
Cell division control protein 6 homolog (CDC6)	OTX93FE7	CDC6_HUMAN	Gene/Protein Processing	[3]
Centrin-2 (CETN2)	OTJTTGS0	CETN2_HUMAN	Gene/Protein Processing	[3]
Cohesin subunit SA-2 (STAG2)	OTR6X1Q7	STAG2_HUMAN	Gene/Protein Processing	[3]
Collagenase 3 (MMP13)	OTY8BZIE	MMP13_HUMAN	Gene/Protein Processing	[3]
Condensin complex subunit 1 (NCAPD2)	OT8VGE2O	CND1_HUMAN	Gene/Protein Processing	[3]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7505).
• [2] Histone deacetylase inhibitors in cancer therapy: latest developments, trends and medicinal chemistry perspective. Anticancer Agents Med Chem. 2007 Sep;7(5):576-92.
• [3] Histone deacetylase inhibitor scriptaid induces cell cycle arrest and epigenetic change in colon cancer cells. Int J Oncol. 2008 Oct;33(4):767-76.
• [4] Protein methyltransferases as a target class for drug discovery. Nat Rev Drug Discov. 2009 Sep;8(9):724-32.
• [5] Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
• [6] Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
• [7] Emerging drugs for the therapy of primary and post essential thrombocythemia, post polycythemia vera myelofibrosis. Expert Opin Emerg Drugs. 2009 Sep;14(3):471-9.
• [8] NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma. Blood. 2003 Oct 1;102(7):2615-22.
• [9] Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127.
• [10] Emerging disease-modifying therapies for the treatment of motor neuron disease/amyotropic lateral sclerosis. Expert Opin Emerg Drugs. 2007 May;12(2):229-52.
• [11] 2011 Pipeline of 4SC AG.
• [12] Minimal peroxide exposure of neuronal cells induces multifaceted adaptive responses. PLoS One. 2010 Dec 17;5(12):e14352. doi: 10.1371/journal.pone.0014352.
• [13] Effects of 1alpha,25 dihydroxyvitamin D3 and testosterone on miRNA and mRNA expression in LNCaP cells. Mol Cancer. 2011 May 18;10:58.
• [14] Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
• [15] Development and validation of the TGx-HDACi transcriptomic biomarker to detect histone deacetylase inhibitors in human TK6 cells. Arch Toxicol. 2021 May;95(5):1631-1645. doi: 10.1007/s00204-021-03014-2. Epub 2021 Mar 26.
• [16] Clinical response to Nabiximols correlates with the downregulation of immune pathways in multiple sclerosis. Eur J Neurol. 2018 Jul;25(7):934-e70. doi: 10.1111/ene.13623. Epub 2018 Apr 16.
• [17] Inhibition of BRD4 attenuates tumor cell self-renewal and suppresses stem cell signaling in MYC driven medulloblastoma. Oncotarget. 2014 May 15;5(9):2355-71.
• [18] Cannabidiol Displays Proteomic Similarities to Antipsychotics in Cuprizone-Exposed Human Oligodendrocytic Cell Line MO3.13. Front Mol Neurosci. 2021 May 28;14:673144. doi: 10.3389/fnmol.2021.673144. eCollection 2021.
• [19] Development of a neural teratogenicity test based on human embryonic stem cells: response to retinoic acid exposure. Toxicol Sci. 2011 Dec;124(2):370-7.
• [20] Temporal changes in gene expression in the skin of patients treated with isotretinoin provide insight into its mechanism of action. Dermatoendocrinol. 2009 May;1(3):177-87.
• [21] Stem cell transcriptome responses and corresponding biomarkers that indicate the transition from adaptive responses to cytotoxicity. Chem Res Toxicol. 2017 Apr 17;30(4):905-922.
• [22] Quantitative proteomics reveals a broad-spectrum antiviral property of ivermectin, benefiting for COVID-19 treatment. J Cell Physiol. 2021 Apr;236(4):2959-2975. doi: 10.1002/jcp.30055. Epub 2020 Sep 22.
• [23] Gene expression signatures after ethanol exposure in differentiating embryoid bodies. Toxicol In Vitro. 2018 Feb;46:66-76.
• [24] Physiological and toxicological transcriptome changes in HepG2 cells exposed to copper. Physiol Genomics. 2009 Aug 7;38(3):386-401.
• [25] Prenatal arsenic exposure and the epigenome: identifying sites of 5-methylcytosine alterations that predict functional changes in gene expression in newborn cord blood and subsequent birth outcomes. Toxicol Sci. 2015 Jan;143(1):97-106. doi: 10.1093/toxsci/kfu210. Epub 2014 Oct 10.
• [26] Gene expression analysis of precision-cut human liver slices indicates stable expression of ADME-Tox related genes. Toxicol Appl Pharmacol. 2011 May 15;253(1):57-69.
• [27] Global molecular effects of tocilizumab therapy in rheumatoid arthritis synovium. Arthritis Rheumatol. 2014 Jan;66(1):15-23.
• [28] Inhibition of prostate cancer cell colony formation by the flavonoid quercetin correlates with modulation of specific regulatory genes. Clin Diagn Lab Immunol. 2004 Jan;11(1):63-9. doi: 10.1128/cdli.11.1.63-69.2004.
• [29] Motexafin gadolinium and zinc induce oxidative stress responses and apoptosis in B-cell lymphoma lines. Cancer Res. 2005 Dec 15;65(24):11676-88.
• [30] Activation of the p38 MAPK/Akt/ERK1/2 signal pathways is required for the protein stabilization of CDC6 and cyclin D1 in low-dose arsenite-induced cell proliferation. J Cell Biochem. 2010 Dec 15;111(6):1546-55. doi: 10.1002/jcb.22886.
• [31] Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
• [32] Transcriptional profiling of testosterone-regulated genes in the skeletal muscle of human immunodeficiency virus-infected men experiencing weight loss. J Clin Endocrinol Metab. 2007 Jul;92(7):2793-802. doi: 10.1210/jc.2006-2722. Epub 2007 Apr 17.
• [33] Human embryonic stem cell-derived test systems for developmental neurotoxicity: a transcriptomics approach. Arch Toxicol. 2013 Jan;87(1):123-43.
• [34] Repurposing L-menthol for systems medicine and cancer therapeutics? L-menthol induces apoptosis through caspase 10 and by suppressing HSP90. OMICS. 2016 Jan;20(1):53-64.
• [35] Temozolomide induces activation of Wnt/-catenin signaling in glioma cells via PI3K/Akt pathway: implications in glioma therapy. Cell Biol Toxicol. 2020 Jun;36(3):273-278. doi: 10.1007/s10565-019-09502-7. Epub 2019 Nov 22.
• [36] Transcriptional and Metabolic Dissection of ATRA-Induced Granulocytic Differentiation in NB4 Acute Promyelocytic Leukemia Cells. Cells. 2020 Nov 5;9(11):2423. doi: 10.3390/cells9112423.
• [37] Integrating multiple omics to unravel mechanisms of Cyclosporin A induced hepatotoxicity in vitro. Toxicol In Vitro. 2015 Apr;29(3):489-501.
• [38] The thioxotriazole copper(II) complex A0 induces endoplasmic reticulum stress and paraptotic death in human cancer cells. J Biol Chem. 2009 Sep 4;284(36):24306-19.
• [39] Bromodomain-containing protein 4 (BRD4) regulates RNA polymerase II serine 2 phosphorylation in human CD4+ T cells. J Biol Chem. 2012 Dec 14;287(51):43137-55.
• [40] Air pollution and DNA methylation alterations in lung cancer: A systematic and comparative study. Oncotarget. 2017 Jan 3;8(1):1369-1391. doi: 10.18632/oncotarget.13622.
• [41] Comprehensive analysis of transcriptomic changes induced by low and high doses of bisphenol A in HepG2 spheroids in vitro and rat liver in vivo. Environ Res. 2019 Jun;173:124-134. doi: 10.1016/j.envres.2019.03.035. Epub 2019 Mar 18.
• [42] Analysis of the prostate cancer cell line LNCaP transcriptome using a sequencing-by-synthesis approach. BMC Genomics. 2006 Sep 29;7:246. doi: 10.1186/1471-2164-7-246.
• [43] mTOR inhibition reverses acquired endocrine therapy resistance of breast cancer cells at the cell proliferation and gene-expression levels. Cancer Sci. 2008 Oct;99(10):1992-2003. doi: 10.1111/j.1349-7006.2008.00955.x.
• [44] Time series analysis of oxidative stress response patterns in HepG2: a toxicogenomics approach. Toxicology. 2013 Apr 5;306:24-34.
• [45] Methotrexate modulates folate phenotype and inflammatory profile in EA.hy 926 cells. Eur J Pharmacol. 2014 Jun 5;732:60-7.
• [46] Multifaceted preventive effects of single agent quercetin on a human prostate adenocarcinoma cell line (PC-3): implications for nutritional transcriptomics and multi-target therapy. Med Oncol. 2011 Dec;28(4):1395-404. doi: 10.1007/s12032-010-9603-3. Epub 2010 Jul 2.
• [47] Effects of ciglitazone and troglitazone on the proliferation of human stomach cancer cells. World J Gastroenterol. 2009 Jan 21;15(3):310-20.
• [48] Essential role of cell cycle regulatory genes p21 and p27 expression in inhibition of breast cancer cells by arsenic trioxide. Med Oncol. 2011 Dec;28(4):1225-54.
• [49] Endoplasmic reticulum stress and MAPK signaling pathway activation underlie leflunomide-induced toxicity in HepG2 Cells. Toxicology. 2017 Dec 1;392:11-21.
• [50] Epigenetic activation of O-linked -N-acetylglucosamine transferase overrides the differentiation blockage in acute leukemia. EBioMedicine. 2020 Apr;54:102678. doi: 10.1016/j.ebiom.2020.102678. Epub 2020 Apr 6.
• [51] Activation of AIFM2 enhances apoptosis of human lung cancer cells undergoing toxicological stress. Toxicol Lett. 2016 Sep 6;258:227-236.
• [52] Caffeine disrupts ataxia telangiectasia mutated gene-related pathways and exacerbates acetaminophen toxicity in human fetal immortalized hepatocytes. Toxicology. 2021 Jun 15;457:152811. doi: 10.1016/j.tox.2021.152811. Epub 2021 May 7.
• [53] Exploring pradimicin-IRD antineoplastic mechanisms and related DNA repair pathways. Chem Biol Interact. 2023 Feb 1;371:110342. doi: 10.1016/j.cbi.2023.110342. Epub 2023 Jan 10.
• [54] Definition of transcriptome-based indices for quantitative characterization of chemically disturbed stem cell development: introduction of the STOP-Toxukn and STOP-Toxukk tests. Arch Toxicol. 2017 Feb;91(2):839-864.
• [55] Ethyl carbamate induces cell death through its effects on multiple metabolic pathways. Chem Biol Interact. 2017 Nov 1;277:21-32.
• [56] Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
• [57] Large-scale in silico and microarray-based identification of direct 1,25-dihydroxyvitamin D3 target genes. Mol Endocrinol. 2005 Nov;19(11):2685-95.
• [58] Transcriptomic analysis of untreated and drug-treated differentiated HepaRG cells over a 2-week period. Toxicol In Vitro. 2015 Dec 25;30(1 Pt A):27-35.
• [59] Chemical genomic screening for methylation-silenced genes in gastric cancer cell lines using 5-aza-2'-deoxycytidine treatment and oligonucleotide microarray. Cancer Sci. 2006 Jan;97(1):64-71.
• [60] Identification of novel low-dose bisphenol a targets in human foreskin fibroblast cells derived from hypospadias patients. PLoS One. 2012;7(5):e36711. doi: 10.1371/journal.pone.0036711. Epub 2012 May 4.
• [61] Identification by automated screening of a small molecule that selectively eliminates neural stem cells derived from hESCs but not dopamine neurons. PLoS One. 2009 Sep 23;4(9):e7155.
• [62] Blood transcript immune signatures distinguish a subset of people with elevated serum ALT from others given acetaminophen. Clin Pharmacol Ther. 2016 Apr;99(4):432-41.
• [63] Bringing in vitro analysis closer to in vivo: studying doxorubicin toxicity and associated mechanisms in 3D human microtissues with PBPK-based dose modelling. Toxicol Lett. 2018 Sep 15;294:184-192.
• [64] Caffeine overcomes genistein-induced G2/M cell cycle arrest in breast cancer cells. Nutr Cancer. 2008;60(3):382-8.
• [65] Identification of a transcriptomic signature of food-relevant genotoxins in human HepaRG hepatocarcinoma cells. Food Chem Toxicol. 2020 Jun;140:111297. doi: 10.1016/j.fct.2020.111297. Epub 2020 Mar 28.
• [66] Cell-based two-dimensional morphological assessment system to predict cancer drug-induced cardiotoxicity using human induced pluripotent stem cell-derived cardiomyocytes. Toxicol Appl Pharmacol. 2019 Nov 15;383:114761. doi: 10.1016/j.taap.2019.114761. Epub 2019 Sep 15.
• [67] Cannabidiol-induced transcriptomic changes and cellular senescence in human Sertoli cells. Toxicol Sci. 2023 Feb 17;191(2):227-238. doi: 10.1093/toxsci/kfac131.
• [68] Global gene expression analysis reveals differences in cellular responses to hydroxyl- and superoxide anion radical-induced oxidative stress in caco-2 cells. Toxicol Sci. 2010 Apr;114(2):193-203. doi: 10.1093/toxsci/kfp309. Epub 2009 Dec 31.
• [69] CyclinB2 and BIRC5 genes as surrogate biomarkers for neurite outgrowth in SH-SY5Y subclonal cells. Neuropharmacology. 2006 Jun;50(8):1041-7. doi: 10.1016/j.neuropharm.2006.02.004. Epub 2006 Mar 30.
• [70] Effects of chlorpromazine with and without UV irradiation on gene expression of HepG2 cells. Mutat Res. 2005 Aug 4;575(1-2):47-60. doi: 10.1016/j.mrfmmm.2005.03.002. Epub 2005 Apr 26.
• [71] Classification of heavy-metal toxicity by human DNA microarray analysis. Environ Sci Technol. 2007 May 15;41(10):3769-74.
• [72] ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
• [73] Comparative proteomics reveals concordant and discordant biochemical effects of caffeine versus epigallocatechin-3-gallate in human endothelial cells. Toxicol Appl Pharmacol. 2019 Sep 1;378:114621. doi: 10.1016/j.taap.2019.114621. Epub 2019 Jun 10.
• [74] DNA methylome-wide alterations associated with estrogen receptor-dependent effects of bisphenols in breast cancer. Clin Epigenetics. 2019 Oct 10;11(1):138. doi: 10.1186/s13148-019-0725-y.
• [75] Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer. J Natl Cancer Inst. 2009 Mar 4;101(5):306-20.
• [76] Differential modulation of PI3-kinase/Akt pathway during all-trans retinoic acid- and Am80-induced HL-60 cell differentiation revealed by DNA microarray analysis. Biochem Pharmacol. 2004 Dec 1;68(11):2177-86.
• [77] Changes in gene expression profiles of multiple myeloma cells induced by arsenic trioxide (ATO): possible mechanisms to explain ATO resistance in vivo. Br J Haematol. 2005 Mar;128(5):636-44.
• [78] The exosome-like vesicles derived from androgen exposed-prostate stromal cells promote epithelial cells proliferation and epithelial-mesenchymal transition. Toxicol Appl Pharmacol. 2021 Jan 15;411:115384. doi: 10.1016/j.taap.2020.115384. Epub 2020 Dec 25.
• [79] Zoledronate dysregulates fatty acid metabolism in renal tubular epithelial cells to induce nephrotoxicity. Arch Toxicol. 2018 Jan;92(1):469-485.
• [80] In vitro evaluation of biomarkers of nephrotoxicity through gene expression using gentamicin. J Biochem Mol Toxicol. 2018 Sep;32(9):e22189. doi: 10.1002/jbt.22189. Epub 2018 Jul 10.
• [81] Comparison of base-line and chemical-induced transcriptomic responses in HepaRG and RPTEC/TERT1 cells using TempO-Seq. Arch Toxicol. 2018 Aug;92(8):2517-2531.
• [82] Arsenic suppresses gene expression in promyelocytic leukemia cells partly through Sp1 oxidation. Blood. 2005 Jul 1;106(1):304-10.
• [83] Cyclosporine A--induced oxidative stress in human renal mesangial cells: a role for ERK 1/2 MAPK signaling. Toxicol Sci. 2012 Mar;126(1):101-13.
• [84] Identification of biomarkers and outcomes of endocrine disruption in human ovarian cortex using In Vitro Models. Toxicology. 2023 Feb;485:153425. doi: 10.1016/j.tox.2023.153425. Epub 2023 Jan 5.
• [85] Apoptosis induced by piroxicam plus cisplatin combined treatment is triggered by p21 in mesothelioma. PLoS One. 2011;6(8):e23569.
• [86] Decrease of plasminogen activator inhibitor-1 may contribute to the anti-invasive action of cannabidiol on human lung cancer cells. Pharm Res. 2010 Oct;27(10):2162-74. doi: 10.1007/s11095-010-0219-2. Epub 2010 Jul 29.
• [87] Unique signatures of stress-induced senescent human astrocytes. Exp Neurol. 2020 Dec;334:113466. doi: 10.1016/j.expneurol.2020.113466. Epub 2020 Sep 17.
• [88] Effect of spironolactone on impaired fibrinolysis of hypertensive patients. Kidney Blood Press Res. 2002;25(4):260-4. doi: 10.1159/000066348.
• [89] Association of cell cycle arrest with anticancer drug-induced epithelial-mesenchymal transition in alveolar epithelial cells. Toxicology. 2019 Aug 1;424:152231. doi: 10.1016/j.tox.2019.06.002. Epub 2019 Jun 4.
• [90] Simvastatin inhibits tissue factor and plasminogen activator inhibitor-1 secretion by peripheral blood mononuclear cells in patients with primary nephrotic syndrome. Eur J Med Res. 2007 May 29;12(5):216-21.
• [91] Polyphenols downregulate PAI-1 gene expression in cultured human coronary artery endothelial cells: molecular contributor to cardiovascular protection. Thromb Res. 2007;121(1):59-65. doi: 10.1016/j.thromres.2007.02.001. Epub 2007 Mar 26.
• [92] Pharmacotoxicology of clinically-relevant concentrations of obeticholic acid in an organotypic human hepatocyte system. Toxicol In Vitro. 2017 Mar;39:93-103.
• [93] Troglitazone reduces plasminogen activator inhibitor-1 expression and secretion in cultured human adipocytes. Diabetologia. 2000 Mar;43(3):377-83. doi: 10.1007/s001250050057.
• [94] Robustness testing and optimization of an adverse outcome pathway on cholestatic liver injury. Arch Toxicol. 2020 Apr;94(4):1151-1172. doi: 10.1007/s00204-020-02691-9. Epub 2020 Mar 10.
• [95] Arsenic trioxide induces different gene expression profiles of genes related to growth and apoptosis in glioma cells dependent on the p53 status. Mol Biol Rep. 2008 Sep;35(3):421-9.
• [96] Cannabidiol Modulates the Immunophenotype and Inhibits the Activation of the Inflammasome in Human Gingival Mesenchymal Stem Cells. Front Physiol. 2016 Nov 24;7:559. doi: 10.3389/fphys.2016.00559. eCollection 2016.
• [97] Analysis of estrogen agonism and antagonism of tamoxifen, raloxifene, and ICI182780 in endometrial cancer cells: a putative role for the epidermal growth factor receptor ligand amphiregulin. J Soc Gynecol Investig. 2005 Oct;12(7):e55-67.
• [98] Identification of genes linked to gefitinib treatment in prostate cancer cell lines with or without resistance to androgen: a clue to application of gefitinib to hormone-resistant prostate cancer. Oncol Rep. 2006 Jun;15(6):1453-60.
• [99] MS4A3-HSP27 target pathway reveals potential for haematopoietic disorder treatment in alimentary toxic aleukia. Cell Biol Toxicol. 2023 Feb;39(1):201-216. doi: 10.1007/s10565-021-09639-4. Epub 2021 Sep 28.
• [100] Antirheumatic drug response signatures in human chondrocytes: potential molecular targets to stimulate cartilage regeneration. Arthritis Res Ther. 2009;11(1):R15.
• [101] Systems analysis of transcriptome and proteome in retinoic acid/arsenic trioxide-induced cell differentiation/apoptosis of promyelocytic leukemia. Proc Natl Acad Sci U S A. 2005 May 24;102(21):7653-8.
• [102] Keratinocyte-derived IL-36gama plays a role in hydroquinone-induced chemical leukoderma through inhibition of melanogenesis in human epidermal melanocytes. Arch Toxicol. 2019 Aug;93(8):2307-2320.
• [103] Moving toward integrating gene expression profiling into high-throughput testing: a gene expression biomarker accurately predicts estrogen receptor alpha modulation in a microarray compendium. Toxicol Sci. 2016 May;151(1):88-103.
• [104] A Gene Expression Biomarker Identifies Chemical Modulators of Estrogen Receptor in an MCF-7 Microarray Compendium. Chem Res Toxicol. 2021 Feb 15;34(2):313-329. doi: 10.1021/acs.chemrestox.0c00243. Epub 2021 Jan 6.
• [105] Single-cell Transcriptome Mapping Identifies Common and Cell-type Specific Genes Affected by Acute Delta9-tetrahydrocannabinol in Humans. Sci Rep. 2020 Feb 26;10(1):3450. doi: 10.1038/s41598-020-59827-1.
• [106] The neuroprotective action of the mood stabilizing drugs lithium chloride and sodium valproate is mediated through the up-regulation of the homeodomain protein Six1. Toxicol Appl Pharmacol. 2009 Feb 15;235(1):124-34.
• [107] Functional gene expression profile underlying methotrexate-induced senescence in human colon cancer cells. Tumour Biol. 2011 Oct;32(5):965-76.
• [108] Phenotypic characterization of retinoic acid differentiated SH-SY5Y cells by transcriptional profiling. PLoS One. 2013 May 28;8(5):e63862.
• [109] A transcriptome-based classifier to identify developmental toxicants by stem cell testing: design, validation and optimization for histone deacetylase inhibitors. Arch Toxicol. 2015 Sep;89(9):1599-618.
• [110] Chronic occupational exposure to arsenic induces carcinogenic gene signaling networks and neoplastic transformation in human lung epithelial cells. Toxicol Appl Pharmacol. 2012 Jun 1;261(2):204-16.
• [111] DNA array analysis of the effects of aspirin on colon cancer cells: involvement of Rac1. Carcinogenesis. 2004 Jul;25(7):1293-8.
• [112] Gaseous nitrogen oxide promotes human lung cancer cell line A549 migration, invasion, and metastasis via iNOS-mediated MMP-2 production. Toxicol Sci. 2008 Dec;106(2):364-75. doi: 10.1093/toxsci/kfn195. Epub 2008 Sep 16.
• [113] Inhibition of invasion and induction of apoptosis by selenium in human malignant brain tumour cells in vitro. Int J Oncol. 2007 May;30(5):1263-71.
• [114] Integrated assessment by multiple gene expression analysis of quercetin bioactivity on anticancer-related mechanisms in colon cancer cells in vitro. Eur J Nutr. 2005 Mar;44(3):143-56. doi: 10.1007/s00394-004-0503-1. Epub 2004 Apr 30.
• [115] Retinoic acid remodels extracellular matrix (ECM) of cultured human fetal palate mesenchymal cells (hFPMCs) through down-regulation of TGF-/Smad signaling. Toxicol Lett. 2014 Mar 3;225(2):208-15. doi: 10.1016/j.toxlet.2013.12.013. Epub 2013 Dec 24.
• [116] Arsenic trioxide (As2O3) inhibits invasion of HT1080 human fibrosarcoma cells: role of nuclear factor-kappaB and reactive oxygen species. J Cell Biochem. 2005 Aug 1;95(5):955-69. doi: 10.1002/jcb.20452.
• [117] Expression profile analysis of human peripheral blood mononuclear cells in response to aspirin. Arch Immunol Ther Exp (Warsz). 2005 Mar-Apr;53(2):151-8.
• [118] Tetracaine downregulates matrix metalloproteinase activity and inhibits invasiveness of strongly metastatic MDA-MB-231 human breast cancer cells. Chem Biol Interact. 2023 Nov 1;385:110730. doi: 10.1016/j.cbi.2023.110730. Epub 2023 Oct 7.
• [119] Integrative "-Omics" analysis in primary human hepatocytes unravels persistent mechanisms of cyclosporine A-induced cholestasis. Chem Res Toxicol. 2016 Dec 19;29(12):2164-2174.
• [120] Comparative gene expression profiling reveals partially overlapping but distinct genomic actions of different antiestrogens in human breast cancer cells. J Cell Biochem. 2006 Aug 1;98(5):1163-84.
• [121] Gene expression after treatment with hydrogen peroxide, menadione, or t-butyl hydroperoxide in breast cancer cells. Cancer Res. 2002 Nov 1;62(21):6246-54.
• [122] Retinoic acid receptor alpha amplifications and retinoic acid sensitivity in breast cancers. Clin Breast Cancer. 2013 Oct;13(5):401-8.
• [123] Polyunsaturated fatty acids synergize with lipid droplet binding thalidomide analogs to induce oxidative stress in cancer cells. Lipids Health Dis. 2010 Jun 2;9:56. doi: 10.1186/1476-511X-9-56.
• [124] Febuxostat Increases Ventricular Arrhythmogenesis Through Calcium Handling Dysregulation in Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes. Toxicol Sci. 2022 Sep 24;189(2):216-224. doi: 10.1093/toxsci/kfac073.
• [125] THC exposure of human iPSC neurons impacts genes associated with neuropsychiatric disorders. Transl Psychiatry. 2018 Apr 25;8(1):89. doi: 10.1038/s41398-018-0137-3.
• [126] The proapoptotic effect of zoledronic acid is independent of either the bone microenvironment or the intrinsic resistance to bortezomib of myeloma cells and is enhanced by the combination with arsenic trioxide. Exp Hematol. 2011 Jan;39(1):55-65.
• [127] CD82 gene suppression in endometrial stromal cells leads to increase of the cell invasiveness in the endometriotic milieu. J Mol Endocrinol. 2011 Aug 31;47(2):195-208. doi: 10.1530/JME-10-0165. Print 2011 Oct.
• [128] The contribution of methotrexate exposure and host factors on transcriptional variance in human liver. Toxicol Sci. 2007 Jun;97(2):582-94.
• [129] Peroxisome proliferator activated receptor gamma (PPAR-gama) ligand pioglitazone regulated gene networks in term human primary trophoblast cells. Reprod Toxicol. 2018 Oct;81:99-107.
• [130] In vitro and in vivo irinotecan-induced changes in expression profiles of cell cycle and apoptosis-associated genes in acute myeloid leukemia cells. Mol Cancer Ther. 2005 Jun;4(6):885-900.
• [131] Low doses of cisplatin induce gene alterations, cell cycle arrest, and apoptosis in human promyelocytic leukemia cells. Biomark Insights. 2016 Aug 24;11:113-21.
• [132] 17-Estradiol Activates HSF1 via MAPK Signaling in ER-Positive Breast Cancer Cells. Cancers (Basel). 2019 Oct 11;11(10):1533. doi: 10.3390/cancers11101533.
• [133] Inhibition of autophagic flux differently modulates cannabidiol-induced death in 2D and 3D glioblastoma cell cultures. Sci Rep. 2020 Feb 14;10(1):2687. doi: 10.1038/s41598-020-59468-4.
• [134] Microarray analysis of H2O2-, HNE-, or tBH-treated ARPE-19 cells. Free Radic Biol Med. 2002 Nov 15;33(10):1419-32.
• [135] Sulindac suppresses beta-catenin expression in human cancer cells. Eur J Pharmacol. 2008 Mar 31;583(1):26-31. doi: 10.1016/j.ejphar.2007.12.034. Epub 2008 Feb 5.
• [136] Multifaceted suppression of aggressive behavior of thyroid carcinoma by all-trans retinoic acid induced re-differentiation. Mol Cell Endocrinol. 2012 Jan 2;348(1):260-9. doi: 10.1016/j.mce.2011.09.002. Epub 2011 Sep 6.
• [137] Arsenic trioxide and 2-methoxyestradiol reduce beta-catenin accumulation after proteasome inhibition and enhance the sensitivity of myeloma cells to Bortezomib. Leuk Res. 2008 Nov;32(11):1674-83. doi: 10.1016/j.leukres.2008.03.039. Epub 2008 May 15.
• [138] Effect of aspirin on the Wnt/beta-catenin pathway is mediated via protein phosphatase 2A. Oncogene. 2006 Oct 19;25(49):6447-56. doi: 10.1038/sj.onc.1209658. Epub 2006 Jul 31.
• [139] Benzene metabolite hydroquinone induces apoptosis of bone marrow mononuclear cells through inhibition of -catenin signaling. Toxicol In Vitro. 2018 Feb;46:361-369. doi: 10.1016/j.tiv.2017.08.018. Epub 2017 Sep 5.
• [140] Anti-androgen 2-hydroxyflutamide modulates cadherin, catenin and androgen receptor phosphorylation in androgen-sensitive LNCaP and androgen-independent PC3 prostate cancer cell lines acting via PI3K/Akt and MAPK/ERK1/2 pathways. Toxicol In Vitro. 2017 Apr;40:324-335. doi: 10.1016/j.tiv.2017.01.019. Epub 2017 Feb 2.
• [141] Anthelmintic Niclosamide Disrupts the Interplay of p65 and FOXM1/-catenin and Eradicates Leukemia Stem Cells in Chronic Myelogenous Leukemia. Clin Cancer Res. 2017 Feb 1;23(3):789-803. doi: 10.1158/1078-0432.CCR-16-0226. Epub 2016 Aug 4.
• [142] Genistein and bisphenol A exposure cause estrogen receptor 1 to bind thousands of sites in a cell type-specific manner. Genome Res. 2012 Nov;22(11):2153-62.
• [143] A trichostatin A expression signature identified by TempO-Seq targeted whole transcriptome profiling. PLoS One. 2017 May 25;12(5):e0178302. doi: 10.1371/journal.pone.0178302. eCollection 2017.
• [144] Simvastatin inactivates beta1-integrin and extracellular signal-related kinase signaling and inhibits cell proliferation in head and neck squamous cell carcinoma cells. Cancer Sci. 2007 Jun;98(6):890-9.
• [145] Gene expression profile changes in NB4 cells induced by arsenic trioxide. Acta Pharmacol Sin. 2003 Jul;24(7):646-50.
• [146] Ouabain impairs cell migration, and invasion and alters gene expression of human osteosarcoma U-2 OS cells. Environ Toxicol. 2017 Nov;32(11):2400-2413. doi: 10.1002/tox.22453. Epub 2017 Aug 10.
• [147] Arsenite and cadmium promote the development of mammary tumors. Carcinogenesis. 2020 Jul 14;41(7):1005-1014. doi: 10.1093/carcin/bgz176.
• [148] Multiple microRNAs function as self-protective modules in acetaminophen-induced hepatotoxicity in humans. Arch Toxicol. 2018 Feb;92(2):845-858.
• [149] Phenethyl isothiocyanate alters the gene expression and the levels of protein associated with cell cycle regulation in human glioblastoma GBM 8401 cells. Environ Toxicol. 2017 Jan;32(1):176-187.
• [150] Novel ATP-competitive Akt inhibitor afuresertib suppresses the proliferation of malignant pleural mesothelioma cells. Cancer Med. 2017 Nov;6(11):2646-2659. doi: 10.1002/cam4.1179. Epub 2017 Sep 27.
• [151] Contrasting effects of fluoroquinolone antibiotics on the expression of the collagenases, matrix metalloproteinases (MMP)-1 and -13, in human tendon-derived cells. Rheumatology (Oxford). 2005 Dec;44(12):1514-7. doi: 10.1093/rheumatology/kei087. Epub 2005 Sep 7.
• [152] Chloramphenicol causes mitochondrial stress, decreases ATP biosynthesis, induces matrix metalloproteinase-13 expression, and solid-tumor cell invasion. Toxicol Sci. 2010 Jul;116(1):140-50. doi: 10.1093/toxsci/kfq085. Epub 2010 Mar 25.
• [153] Matrix metalloproteinases of epithelial origin in facial sebum of patients with acne and their regulation by isotretinoin. J Invest Dermatol. 2005 Oct;125(4):673-84. doi: 10.1111/j.0022-202X.2005.23848.x.
• [154] Glucosamine promotes chondrogenic phenotype in both chondrocytes and mesenchymal stem cells and inhibits MMP-13 expression and matrix degradation. Osteoarthritis Cartilage. 2007 Jun;15(6):646-55. doi: 10.1016/j.joca.2007.01.014. Epub 2007 Mar 6.
• [155] Identification of transcriptome signatures and biomarkers specific for potential developmental toxicants inhibiting human neural crest cell migration. Arch Toxicol. 2016 Jan;90(1):159-80.
• [156] Expression profiling in squamous carcinoma cells reveals pleiotropic effects of vitamin D3 analog EB1089 signaling on cell proliferation, differentiation, and immune system regulation. Mol Endocrinol. 2002 Jun;16(6):1243-56.
• [157] Retinoic acid-induced downmodulation of telomerase activity in human cancer cells. Exp Mol Pathol. 2005 Oct;79(2):108-17.
• [158] Transcriptomics hit the target: monitoring of ligand-activated and stress response pathways for chemical testing. Toxicol In Vitro. 2015 Dec 25;30(1 Pt A):7-18.
• [159] Characterization of formaldehyde's genotoxic mode of action by gene expression analysis in TK6 cells. Arch Toxicol. 2013 Nov;87(11):1999-2012.
• [160] Mitochondrial Uncoupling Induces Epigenome Remodeling and Promotes Differentiation in Neuroblastoma. Cancer Res. 2023 Jan 18;83(2):181-194. doi: 10.1158/0008-5472.CAN-22-1029.
• [161] Identification of vitamin D3 target genes in human breast cancer tissue. J Steroid Biochem Mol Biol. 2016 Nov;164:90-97.
• [162] Bone marrow osteoblast damage by chemotherapeutic agents. PLoS One. 2012;7(2):e30758. doi: 10.1371/journal.pone.0030758. Epub 2012 Feb 17.
• [163] Gene expression profiling of breast cancer cells in response to gemcitabine: NF-kappaB pathway activation as a potential mechanism of resistance. Breast Cancer Res Treat. 2007 Apr;102(2):157-72.
• [164] Effect of prenatal arsenic exposure on DNA methylation and leukocyte subpopulations in cord blood. Epigenetics. 2014 May;9(5):774-82. doi: 10.4161/epi.28153. Epub 2014 Feb 13.
• [165] Predictive toxicology using systemic biology and liver microfluidic "on chip" approaches: application to acetaminophen injury. Toxicol Appl Pharmacol. 2012 Mar 15;259(3):270-80.
• [166] p19INK4D and cell death. Cell Cycle. 2006 Mar;5(6):596-8. doi: 10.4161/cc.5.6.2585. Epub 2006 Mar 15.
• [167] Simvastatin inhibits cell growth and induces apoptosis and G0/G1 cell cycle arrest in hepatic cancer cells. Int J Mol Med. 2010 Nov;26(5):735-41. doi: 10.3892/ijmm_00000520.
• [168] Arsenic trioxide and cisplatin synergism increase cytotoxicity in human ovarian cancer cells: therapeutic potential for ovarian cancer. Cancer Sci. 2009 Dec;100(12):2459-64.
• [169] A genomic approach to predict synergistic combinations for breast cancer treatment. Pharmacogenomics J. 2013 Feb;13(1):94-104. doi: 10.1038/tpj.2011.48. Epub 2011 Nov 15.
• [170] Gypenosides protect retinal pigment epithelium cells from oxidative stress. Food Chem Toxicol. 2018 Feb;112:76-85.
• [171] Capsaicin inhibits the migration, invasion and EMT of renal cancer cells by inducing AMPK/mTOR-mediated autophagy. Chem Biol Interact. 2022 Oct 1;366:110043. doi: 10.1016/j.cbi.2022.110043. Epub 2022 Aug 28.
• [172] Mifepristone induced progesterone withdrawal reveals novel regulatory pathways in human endometrium. Mol Hum Reprod. 2007 Sep;13(9):641-54.
• [173] Fluoxetine mediates G0/G1 arrest by inducing functional inhibition of cyclin dependent kinase subunit (CKS)1. Biochem Pharmacol. 2008 May 15;75(10):1924-34. doi: 10.1016/j.bcp.2008.02.013. Epub 2008 Feb 17.
• [174] Dasatinib reverses cancer-associated fibroblasts (CAFs) from primary lung carcinomas to a phenotype comparable to that of normal fibroblasts. Mol Cancer. 2010 Jun 27;9:168.
• [175] Analysis of gene expression induced by diethylstilbestrol (DES) in human primitive Mullerian duct cells using microarray. Cancer Lett. 2005 Apr 8;220(2):197-210.
• [176] Death-associated protein 5 (DAP5/p97/NAT1) contributes to retinoic acid-induced granulocytic differentiation and arsenic trioxide-induced apoptosis in acute promyelocytic leukemia. Apoptosis. 2008 Jul;13(7):915-28. doi: 10.1007/s10495-008-0222-9.
• [177] Gene Expression Regulation and Pathway Analysis After Valproic Acid and Carbamazepine Exposure in a Human Embryonic Stem Cell-Based Neurodevelopmental Toxicity Assay. Toxicol Sci. 2015 Aug;146(2):311-20. doi: 10.1093/toxsci/kfv094. Epub 2015 May 15.
• [178] Mechanism of cisplatin proximal tubule toxicity revealed by integrating transcriptomics, proteomics, metabolomics and biokinetics. Toxicol In Vitro. 2015 Dec 25;30(1 Pt A):117-27.
• [179] Genomic profiling uncovers a molecular pattern for toxicological characterization of mutagens and promutagens in vitro. Toxicol Sci. 2011 Jul;122(1):185-97.
• [180] Cdk4/6 inhibition induces epithelial-mesenchymal transition and enhances invasiveness in pancreatic cancer cells. Mol Cancer Ther. 2012 Oct;11(10):2138-48. doi: 10.1158/1535-7163.MCT-12-0562. Epub 2012 Aug 6.
• [181] Cannabidiol enhances cytotoxicity of anti-cancer drugs in human head and neck squamous cell carcinoma. Sci Rep. 2020 Nov 26;10(1):20622. doi: 10.1038/s41598-020-77674-y.
• [182] The retinoid anticancer signal: mechanisms of target gene regulation. Br J Cancer. 2005 Aug 8;93(3):310-8. doi: 10.1038/sj.bjc.6602700.
• [183] Cannabis-induced cytotoxicity in leukemic cell lines: the role of the cannabinoid receptors and the MAPK pathway. Blood. 2005 Feb 1;105(3):1214-21. doi: 10.1182/blood-2004-03-1182. Epub 2004 Sep 28.
• [184] Integrated analysis of rifampicin-induced microRNA and gene expression changes in human hepatocytes. Drug Metab Pharmacokinet. 2014;29(4):333-40.
• [185] Delta9-tetrahydrocannabinol inhibits cytotrophoblast cell proliferation and modulates gene transcription. Mol Hum Reprod. 2006 May;12(5):321-33. doi: 10.1093/molehr/gal036. Epub 2006 Apr 5.
• [186] Expression profile analysis of colon cancer cells in response to sulindac or aspirin. Biochem Biophys Res Commun. 2002 Mar 29;292(2):498-512.
• [187] The Bromodomain Inhibitor JQ1 and the Histone Deacetylase Inhibitor Panobinostat Synergistically Reduce N-Myc Expression and Induce Anticancer Effects. Clin Cancer Res. 2016 May 15;22(10):2534-44. doi: 10.1158/1078-0432.CCR-15-1666. Epub 2016 Jan 5.
• [188] Quantitative phosphoproteomics reveal cellular responses from caffeine, coumarin and quercetin in treated HepG2 cells. Toxicol Appl Pharmacol. 2022 Aug 15;449:116110. doi: 10.1016/j.taap.2022.116110. Epub 2022 Jun 7.
• [189] Transcriptional profiling of lactic acid treated reconstructed human epidermis reveals pathways underlying stinging and itch. Toxicol In Vitro. 2019 Jun;57:164-173.
• [190] Exposure to Insecticides Modifies Gene Expression and DNA Methylation in Hematopoietic Tissues In Vitro. Int J Mol Sci. 2023 Mar 26;24(7):6259. doi: 10.3390/ijms24076259.
• [191] Impact of Heat Shock Protein 90 Inhibition on the Proteomic Profile of Lung Adenocarcinoma as Measured by Two-Dimensional Electrophoresis Coupled with Mass Spectrometry. Cells. 2019 Jul 31;8(8):806. doi: 10.3390/cells8080806.
• [192] CCAT1 is an enhancer-templated RNA that predicts BET sensitivity in colorectal cancer. J Clin Invest. 2016 Feb;126(2):639-52.
• [193] Quercetin potentiates apoptosis by inhibiting nuclear factor-kappaB signaling in H460 lung cancer cells. Biol Pharm Bull. 2013;36(6):944-51. doi: 10.1248/bpb.b12-01004.
• [194] Anti-oncogenic and pro-differentiation effects of clorgyline, a monoamine oxidase A inhibitor, on high grade prostate cancer cells. BMC Med Genomics. 2009 Aug 20;2:55. doi: 10.1186/1755-8794-2-55.
• [195] Effects of lithium and valproic acid on gene expression and phenotypic markers in an NT2 neurosphere model of neural development. PLoS One. 2013;8(3):e58822.
• [196] Interleukin-19 as a translational indicator of renal injury. Arch Toxicol. 2015 Jan;89(1):101-6.
• [197] Reproducible chemical-induced changes in gene expression profiles in human hepatoma HepaRG cells under various experimental conditions. Toxicol In Vitro. 2009 Apr;23(3):466-75. doi: 10.1016/j.tiv.2008.12.018. Epub 2008 Dec 30.
• [198] Identification of mechanisms of action of bisphenol a-induced human preadipocyte differentiation by transcriptional profiling. Obesity (Silver Spring). 2014 Nov;22(11):2333-43.
• [199] Oxidative stress modulates theophylline effects on steroid responsiveness. Biochem Biophys Res Commun. 2008 Dec 19;377(3):797-802.
• [200] Differential responses to retinoic acid and endocrine disruptor compounds of subpopulations within human embryonic stem cell lines. Differentiation. 2012 Nov;84(4):330-43. doi: 10.1016/j.diff.2012.07.006. Epub 2012 Aug 18.
• [201] Inhibition of 5alpha-reductase enhances testosterone-induced expression of U19/Eaf2 tumor suppressor during the regrowth of LNCaP xenograft tumor in nude mice. Prostate. 2010 Oct 1;70(14):1575-85. doi: 10.1002/pros.21193.
• [202] Screening autism-associated environmental factors in differentiating human neural progenitors with fractional factorial design-based transcriptomics. Sci Rep. 2023 Jun 29;13(1):10519. doi: 10.1038/s41598-023-37488-0.
• [203] Isoproterenol effects evaluated in heart slices of human and rat in comparison to rat heart in vivo. Toxicol Appl Pharmacol. 2014 Jan 15;274(2):302-12.
• [204] Acute hypersensitivity of pluripotent testicular cancer-derived embryonal carcinoma to low-dose 5-aza deoxycytidine is associated with global DNA Damage-associated p53 activation, anti-pluripotency and DNA demethylation. PLoS One. 2012;7(12):e53003. doi: 10.1371/journal.pone.0053003. Epub 2012 Dec 27.
• [205] Long-term estrogen exposure promotes carcinogen bioactivation, induces persistent changes in gene expression, and enhances the tumorigenicity of MCF-7 human breast cancer cells. Toxicol Appl Pharmacol. 2009 Nov 1;240(3):355-66.
• [206] Effects of nicotine and lipopolysaccharide on the expression of matrix metalloproteinases, plasminogen activators, and their inhibitors in human osteoblasts. Arch Oral Biol. 2009 Feb;54(2):146-55.
• [207] Utilization of CDKN1A/p21 gene for class discrimination of DNA damage-induced clastogenicity. Toxicology. 2014 Jan 6;315:8-16. doi: 10.1016/j.tox.2013.10.009. Epub 2013 Nov 6.
• [208] Quercetin induced cell apoptosis and altered gene expression in AGS human gastric cancer cells. Environ Toxicol. 2018 Nov;33(11):1168-1181. doi: 10.1002/tox.22623. Epub 2018 Aug 27.
• [209] A comparative transcriptomic study on the effects of valproic acid on two different hESCs lines in a neural teratogenicity test system. Toxicol Lett. 2014 Nov 18;231(1):38-44.
• [210] Gene expression profiling in Ishikawa cells: a fingerprint for estrogen active compounds. Toxicol Appl Pharmacol. 2009 Apr 1;236(1):85-96.
• [211] From transient transcriptome responses to disturbed neurodevelopment: role of histone acetylation and methylation as epigenetic switch between reversible and irreversible drug effects. Arch Toxicol. 2014 Jul;88(7):1451-68.
• [212] Inter-laboratory comparison of human renal proximal tubule (HK-2) transcriptome alterations due to Cyclosporine A exposure and medium exhaustion. Toxicol In Vitro. 2009 Apr;23(3):486-99.
• [213] Design principles of concentration-dependent transcriptome deviations in drug-exposed differentiating stem cells. Chem Res Toxicol. 2014 Mar 17;27(3):408-20.
• [214] A transcriptomics-based in vitro assay for predicting chemical genotoxicity in vivo. Carcinogenesis. 2012 Jul;33(7):1421-9.
• [215] Gene expression changes in primary human nasal epithelial cells exposed to formaldehyde in vitro. Toxicol Lett. 2010 Oct 5;198(2):289-95.
• [216] Gene expression profile and cytotoxicity of human bronchial epithelial cells exposed to crotonaldehyde. Toxicol Lett. 2010 Aug 16;197(2):113-22.
• [217] Inhibiting ubiquitination causes an accumulation of SUMOylated newly synthesized nuclear proteins at PML bodies. J Biol Chem. 2019 Oct 18;294(42):15218-15234. doi: 10.1074/jbc.RA119.009147. Epub 2019 Jul 8.
• [218] Global effects of inorganic arsenic on gene expression profile in human macrophages. Mol Immunol. 2009 Feb;46(4):649-56.
• [219] Environmental pollutant induced cellular injury is reflected in exosomes from placental explants. Placenta. 2020 Jan 1;89:42-49. doi: 10.1016/j.placenta.2019.10.008. Epub 2019 Oct 17.
• [220] Transcriptome profile analysis of saturated aliphatic aldehydes reveals carbon number-specific molecules involved in pulmonary toxicity. Chem Res Toxicol. 2014 Aug 18;27(8):1362-70.
• [221] Transcriptome and DNA methylation changes modulated by sulforaphane induce cell cycle arrest, apoptosis, DNA damage, and suppression of proliferation in human liver cancer cells. Food Chem Toxicol. 2020 Feb;136:111047. doi: 10.1016/j.fct.2019.111047. Epub 2019 Dec 12.
• [222] Folic acid supplementation dysregulates gene expression in lymphoblastoid cells--implications in nutrition. Biochem Biophys Res Commun. 2011 Sep 9;412(4):688-92. doi: 10.1016/j.bbrc.2011.08.027. Epub 2011 Aug 16.
• [223] PPARgamma controls CD1d expression by turning on retinoic acid synthesis in developing human dendritic cells. J Exp Med. 2006 Oct 2;203(10):2351-62.
• [224] Arsenic targets Pin1 and cooperates with retinoic acid to inhibit cancer-driving pathways and tumor-initiating cells. Nat Commun. 2018 Aug 9;9(1):3069. doi: 10.1038/s41467-018-05402-2.